Biotinylated Human CLDN18.2 (N-6His, C-Avi)V2

Item number: EPT259
Availability: In Stock
$2,159.00
$2,159.00
Please hurry! Only 100 left in stock

Documents

Size: 100ug
Subtotal: $2,159.00
10 customers are viewing this product

Customized & fast shipping

Terms and Conditions

Biotinylated Human CLDN18.2 (N-6His, C-Avi)V2

Biotinylated Human CLDN18.2 (N-6His, C-Avi)V2

$2,159.00

Biotinylated Human CLDN18.2 (N-6His, C-Avi)V2

$2,159.00
Size: 100ug
Description
Biotinylated Recombinant Human CLDN18.2 is produced by our E.coli expression system and the target gene encoding extracellular is expressed with a 6His tag at the N-terminus.
Accession
P56856-2
Molecular weight
12.6 KDa
Apparent molecular weight
13 KDa, reducing conditions
Other names
Claudin-18; CLDN18
Purity
Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin
Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Storage
Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Delivery condition
The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.

Related Products

Recently Viewed Products